Under the agreement, Systagenix will co-market EpiFix, MiMedx’s proprietary biologic implant processed from amniotic tissue. Systagenix will conduct the first phase of the EpiFix global launch throughout the United States, followed by other countries.
MiMedx will continue selling EpiFix through existing distributor channels.
More Articles on Orthopedic Devices:
US Implantable Medical Devices Demand to Increase 7.7% Annually Through 2015
Exactech’s Deferred Prosecution Agreement Expires
BioMimetic Reports 2011 Revenue
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.